Equity Tips- Biocon Hits Record High

Equity tips BIOCON hits record high- Biocon is India’s biggest and fully-integrated, innovation-led biopharmaceutical company. Biocon gains 26.70 points oe 3.08% at 892.25 on NSE after European Medicines Agency accepted for company review, Mylan’s marketing authenticate petition for a proposed biosimilar Trastuzumab.

11:20 –The BSE Biocon Ltd up 29.15 points or 3.37% at 894.75.

Biocon inclusive net profit jump 34.5 percent to Rs 166.60 Crore on 28.2 percent rise in net sales to Rs 972 crore in Q1 June 2016 over Q1 June 2015.

Meanwhile, The BSE Sensex down 16.87 points or 0.06 percent at 27819.04 and The NSE Nifty falls 5.45 points or 0.06% at 8586.75.

Mylan N.V., a global pharmaceutical organization and Biocon reported that the European Medicines Agency (EMA) has acknowledged for survey Mylan’s promoting approval application (MAA) for a proposed biosimilar Trastuzumab, which is utilized to treat certain HER2-positive bosom and gastric growths. Mylan and Biocon, which have co-built up this proposed biosimilar, suspect this might be the main MAA for a Trastuzumab biosimilar acknowledged by the EMA for survey. This recording incorporates systematic, utilitarian and pre-clinical information, and in addition results from the pharmacokinetics (PK) and corroborative adequacy/security worldwide clinical trials for Trastuzumab.

Leave a Reply

Your email address will not be published. Required fields are marked *